权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Discovery and characterization of a novel acylcarnitine transporter in brown adipocytes

棕色脂肪细胞中新型酰基肉碱转运蛋白的发现和表征

基本信息

批准号：
10681400
负责人：
Judith Anne Simcox
金额：
$ 31.1万
依托单位：
UNIVERSITY OF WISCONSIN-MADISON
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-15 至 2027-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10681400
关键词：
Address Adipocytes Adipose tissue Adult Affect American Biological Assay Biological Markers Blood Brown Fat CRISPR library CRISPR screen Cardiovascular Diseases Cardiovascular system Carrier Proteins Cell Culture Techniques Cell membrane Cell physiology Cells Cessation of life ChIP-seq Development Diabetes Mellitus Disease Energy Metabolism Gene Expression Genomics Glucose Health Heart Homeostasis In Vitro Individual Insulin Resistance Knock-out Knowledge Link Lipids Liver Luciferases Mass Spectrum Analysis Mediating Membrane Transport Proteins Metabolic Metabolic Diseases Metabolism Modeling Molecular Mus Non-Insulin-Dependent Diabetes Mellitus Obesity Obesity associated disease Overweight PPAR gamma Pathway interactions Pharmacological Treatment Physiologic Thermoregulation Physiological Plasma Population Primary carcinoma of the liver cells Process Production Regulation Reporter Respiration Signal Transduction Skeletal Muscle Source Supercritical Fluid Chromatography Thermogenesis Time Tissue Sample Tissues Transcript United States Work acylcarnitine aged blood glucose regulation chromatin immunoprecipitation experimental study fatty acid oxidation glucose tolerance glucose uptake improved in vivo in vivo Model insight insulin regulation insulin sensitivity insulin signaling insulin tolerance mouse model novel obesity treatment overexpression prevent promoter protein expression resistance mechanism response solute targeted treatment theories therapeutic target tissue/cell culture uptake

项目摘要

Project Summary/Abstract In the United States, 42% of the population is obese, and this obesity predisposes individuals for several diseases including type 2 diabetes which affects 29 million Americans. One established mechanism for the causal relationship between obesity and type 2 diabetes is the development of lipotoxicity, a state where excess lipids build-up to cause increased ectopic lipid droplets, elevated plasma lipids, and subsequently, decreased cellular insulin signaling. These plasma lipids that are increased with lipotoxicity include acylcarnitines, a key intermediate in fatty acid oxidation. Acylcarnitines are an established biomarker of type 2 diabetes, hepatocellular carcinoma, and cardiovascular disease, and are known to cause insulin resistance. Despite the known importance of plasma acylcarnitines in the development of insulin resistance, we do not know how they are imported into cells, how this uptake is regulated, or how imported acylcarnitines are metabolized once they enter the cell from the circulatory system. In this proposal we examine the regulation of acylcarnitine uptake by transporters we have identified through a CRISPR/Cas9 screen. Through targeted knockout of these transporters, we will conduct cell culture experiments to highlight the precise molecular pathways through which acylcarnitines enter the cell and signal for insulin sensitivity. We will also explore tissue specific loss of acylcarnitines in mouse models to determine the contribution of plasma acylcarnitine uptake on whole-body energy expenditure, glucose regulation, and plasma lipid pools. Finally, we will determine how these transporters for plasma acylcarnitines are regulated in cell culture and tissue samples from mice to establish potential therapeutic targets for the treatment of metabolic disease. The proposed work will address long-standing questions on the molecular regulation of plasma acylcarnitine import, metabolism of acylcarnitines after entry into the cell, and the regulation of insulin sensitivity by acylcarnitines. In terms of translatability, this work will generate a mechanistic understanding of how plasma acylcarnitine abundance is controlled and how plasma acylcarnitines impact disease vulnerability to enable the identification of new targets for the pharmacological treatment of obesity and diabetes.

项目摘要/摘要在美国，42%的人口患有肥胖症，这种肥胖症使个人容易患上几种疾病包括影响2900万美国人的2型糖尿病。一种既定的机制，用于肥胖和2型糖尿病之间的因果关系是脂毒性的发展，一种过度的状态脂类积聚导致异位脂滴增加，血浆脂质升高，随后减少细胞胰岛素信号。这些随着脂肪毒性而增加的血脂包括酰肉碱，一种关键的脂肪酸氧化的中间体。酰肉碱是2型糖尿病的公认生物标记物，肝细胞癌症和心血管疾病，并已知会导致胰岛素抵抗。尽管已知血浆酰卡尼汀在胰岛素抵抗发生发展中的重要性，我们不知道它们是如何发生的进入细胞，这种摄取是如何调节的，或者进口的酰肉碱进入细胞后是如何代谢的循环系统中的细胞。在这项提案中，我们研究了转运蛋白对酰肉碱摄取的调节，我们已经通过一种 CRISPR/CAS9屏幕。通过定向敲除这些转运蛋白，我们将进行细胞培养实验重点介绍酰卡尼汀进入细胞并发出胰岛素信号的确切分子途径敏感度。我们还将在小鼠模型中探索组织特异性的酰肉碱丢失，以确定血浆酰卡尼汀摄取对全身能量消耗、血糖调节和血浆的贡献脂水池。最后，我们将确定这些血浆酰肉碱转运体是如何在细胞中被调节的。从小鼠的培养和组织样本中建立治疗代谢疾病的潜在靶点疾病。拟议的工作将解决长期存在的关于血浆酰肉碱分子调控的问题。酰肉碱的输入、进入细胞后的代谢以及胰岛素敏感性的调节酰基卡尼汀。在可译性方面，这项工作将产生对等离子体如何酰肉碱的丰度受到控制，以及血浆酰肉碱如何影响疾病的易感性，从而使确定肥胖症和糖尿病药物治疗的新靶点。